Your session is about to expire
← Back to Search
Anticoagulant
Apixaban for Deep Vein Thrombosis (VTE Trial)
Phase 2
Waitlist Available
Led By Oya Tugal, MD
Research Sponsored by New York Medical College
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Treatment with apixaban has to begin within 72 hours of the diagnosis of VTE.
Patients who have received heparin at the beginning of their diagnosis and are willing to switch to apixaban, are allowed to do so within 72 hours of their treatment. Patients who are switched to apixaban are not allowed to receive any other systemic anticoagulant therapy.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 8-15
Awards & highlights
VTE Trial Summary
This trial tests whether apixaban is more effective than placebo at preventing a secondary thromboembolism in patients who have already developed a venous thrombosis.
Eligible Conditions
- Deep Vein Thrombosis
VTE Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowVTE Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 8-15
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 8-15
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
venous thromboembolism (VTE) formation
Secondary outcome measures
Doppler ultrasound vein imaging
Side effects data
From 2018 Phase 4 trial • 557 Patients • NCT018843377%
Incision site pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
TOTAL KNEE REPLACEMENT (TKR)
TOTAL HIP REPLACEMENT (THR)
VTE Trial Design
1Treatment groups
Experimental Treatment
Group I: AbixabanExperimental Treatment1 Intervention
Apixaban 10 mg twice daily p.o. for seven days followed by 5 mg twice daily p.o. for children and adolescents weighting ≥40 kg who have been diagnosed with a thrombosis.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Apixaban
FDA approved
Find a Location
Who is running the clinical trial?
New York Medical CollegeLead Sponsor
69 Previous Clinical Trials
5,986 Total Patients Enrolled
Oya Tugal, MDPrincipal InvestigatorNew York Medical College
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger